Attachment
Gates Package, p.253 · gates:exh:00146
Page text: p.253 · original PDF
- Date
- — (unknown precision)
- Type
- attachment · document
Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership
Walter Koroshetz, M.D.
Director
National Institute of Neurological Disorders and Stroke, NIH
Lisa LaVange, Ph.D.
Professor and Associate Chair, Department of Biostatistics
University of North Carolina Gillings School of Global Public Health
Elliot Levy, M.D.
Senior Vice President, Global Development
Amgen
John Mellors, M.D.
Distinguished Professor of Medicine, Chief of Division of Infectious Diseases
University of Pittsburgh School of Medicine
Sandeep Menon, M.D., Ph.D.
Senior Vice President and Head of Early Clinical Development
Pfizer
Naimish Patel, M.D.
Head of Global Development, Immunology and Inflammation Therapeutic Area
Sanofi
Amanda Peppercorn, M.D.
Senior Medical Director, Infectious Disease
GlaxoSmithKline
Mike Poole, M.D., FACP
Therapeutic Accelerator Lead
Bill & Melinda Gates Foundation
Michael Proschan, Ph.D.
Mathematical Statistician, Biostatistics Research Branch
National Institute of Allergy and Infectious Diseases, NIH
Sarah Read, M.D. (Co-Chair)
Deputy Director, Division of AIDS
National Institute of Allergy and Infectious Diseases, NIH
Lora Reineck, M.D., M.S.
Program Director, Acute Lung Injury/Critical Care Program, Division of Lung Diseases
National Heart, Lung, and Blood Institute, NIH
Yves Rosenberg, M.D., M.P.H.
Chief, Atherothrombosis and Coronary Artery Disease Branch
National Heart, Lung, and Blood Institute